Cite
Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?
MLA
Scalais, Emmanuel, et al. “Would, Early, versus Late Hydroxocobalamin Dose Intensification Treatment, Prevent Cognitive Decline, Macular Degeneration and Ocular Disease, in 5 Patients with Early-Onset CblC Deficiency?” Molecular Genetics & Metabolism, vol. 140, no. 3, Nov. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ymgme.2023.107681.
APA
Scalais, E., Geron, C., Pierron, C., Cardillo, S., Schlesser, V., Mataigne, F., Borde, P., & Regal, L. (2023). Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency? Molecular Genetics & Metabolism, 140(3), N.PAG. https://doi.org/10.1016/j.ymgme.2023.107681
Chicago
Scalais, Emmanuel, Christine Geron, Charlotte Pierron, Sandra Cardillo, Vincent Schlesser, Frédéric Mataigne, Patricia Borde, and Luc Regal. 2023. “Would, Early, versus Late Hydroxocobalamin Dose Intensification Treatment, Prevent Cognitive Decline, Macular Degeneration and Ocular Disease, in 5 Patients with Early-Onset CblC Deficiency?” Molecular Genetics & Metabolism 140 (3): N.PAG. doi:10.1016/j.ymgme.2023.107681.